M.F. Alvisi

机构：Mario Negri Institute for Pharmacological Research · ORCID：0000-0003-0348-1527

发表论文 45 篇 · 总被引 461 次 · h-index 11

代表论文

• Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer (2022 · Gynecologic Oncology · 被引 72)
• High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial (2022 · International Journal of Antimicrobial Agents · 被引 58)
• Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts (2021 · British Journal of Cancer · 被引 40)
• Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671) (2024 · Annals of Oncology · 被引 34)
• Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases (2020 · Journal of Crohn s and Colitis · 被引 27)
• BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC) (2019 · Annals of Oncology · 被引 25)